**Bevacizumab**

**Core Concept**
Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. By inhibiting VEGF, bevacizumab disrupts the formation of new blood vessels, thereby reducing tumor growth and metastasis.

**Why the Correct Answer is Right**
Bevacizumab works by binding to VEGF, preventing it from interacting with its receptor (VEGFR) on endothelial cells. This inhibits the downstream signaling pathways that promote angiogenesis, including the PI3K/AKT and MAPK/ERK pathways. As a result, bevacizumab reduces tumor vascularity, leading to decreased tumor growth and progression.

**Why Each Wrong Option is Incorrect**
**Option A:** Bevacizumab is not a chemotherapy agent. It is a targeted therapy that specifically inhibits angiogenesis, rather than directly killing cancer cells.
**Option B:** Bevacizumab does not increase blood flow to the tumor. Instead, it reduces tumor vascularity, which can lead to tumor necrosis and decreased growth.
**Option C:** Bevacizumab is not a hormone therapy. It targets the VEGF pathway, which is involved in angiogenesis, rather than hormone receptors or hormone production.

**Clinical Pearl / High-Yield Fact**
Bevacizumab is often used in combination with chemotherapy or other targeted therapies to improve treatment outcomes in various cancers, including colorectal, breast, and lung cancer. It is essential to monitor for potential side effects, such as hypertension, proteinuria, and thromboembolic events, when using bevacizumab.

**Correct Answer:** D. A recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF).